JP Patent

JP6896703B2 — ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2021-06-30 · 5y expired

What this patent protects

Patent listed against vutrisiran-sodium.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: JP6896703B2
Jurisdiction: JP
Classification: —
Expires: 2021-06-30
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.